Thromboembolism
Drug research and approvals for thromboembolism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 159 studies of thromboembolism are recruiting on ClinicalTrials.gov, Health Canada has authorized 34 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 9 authorised medicines for it.
- Recruiting worldwide: 159
- Trials authorized in Canada: 34
- FDA orphan approvals: 1
- EU medicines: 9
- Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple MyelomaNCT07907211 · Phase 4 · Chen Lijuan · starts Feb 1, 2024
- Danang Cerebral Venous Thrombosis RegistryNCT07890675 · Not reported · Da Nang Hospital · starts Oct 9, 2025
- Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyNCT07869615 · Not applicable · Military Hospital of Tunis · starts Sep 15, 2026
- TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower…NCT07863115 · Not reported · University of Monastir · starts Sep 1, 2025
- Mobilisation After Endovascular Stroke TreatmentNCT07860333 · Not reported · Karolinska Institutet · starts May 7, 2026
- Circadian Variation of Anti-Factor Xa in Hospitalized Trauma PatientsNCT07856641 · Not reported · The University of Texas Health Science Center, Houston · starts Aug 26, 2026
- Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and SurveillanceNCT07855679 · Not reported · Azienda Ospedaliero-Universitaria Careggi · starts Jun 19, 2026
- Vortosiran for VTE PreventionNCT07850453 · Phase 2 · Ribocure Pharmaceuticals AB · starts Nov 4, 2026
- Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis OutcomesNCT07820670 · Not applicable · Wolfson Medical Center · starts Dec 1, 2025
Approved 2
Phase 3 10
- Enoxaparin sodiumAntithrombin-III activator
- Dabigatran etexilateThrombin inhibitor
- Dalteparin sodiumAntithrombin-III activator
- FondaparinuxAntithrombin-III activator
- DabigatranThrombin inhibitor
- XimelagatranThrombin inhibitor
- HeparinAntithrombin-III activator
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- Felbinac
- Certoparin
Phase 2 3
- RivaroxabanCoagulation factor X inhibitor
- DarexabanCoagulation factor X inhibitor
- BetrixabanCoagulation factor X inhibitor
Phase 1 or earlier 4
- ApixabanCoagulation factor X inhibitor
- LidocaineSodium channel alpha subunit blocker
- Frunexian
- Gruticibart
How its trials ended
912 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 220 whose ending is known, 51% met their primary endpoint, 8% missed it and 40% stopped early.
- Completed, result not reported40244%
- Ongoing17419%
- Status unknown11613%
- Met its primary endpoint11312%
- Stopped: other or unclear435%
- Stopped: enrollment or feasibility293%
- Missed its primary endpoint182%
- Stopped: sponsor or business decision81%
- Stopped: lack of efficacy51%
- Stopped: funding4<1%
| Aug 27, 2024 | The partum (postpartum aspirin to reduce thromboembolism undue morbidity) trialAcetylsalicylic acid | Governors of The University of Calgary | Ongoing |
| Jul 29, 2024 | Tranexamic acid to decrease heavy menstrual bleeding in individuals anticoagulated for venous thromboembolism (t-rex hmb) pilot studyTranexamic acid | University Health Network | Pending |
| May 8, 2024 | A master protocol for a phase 2 randomized, double-blind, placebo-controlled study of REGN9933 and REGN7508, monoclonal antibodies against factor xi for…REGN9933 / REGN7508 | Regeneron | Closed |
| May 3, 2024 | Reducing gastrointestinal bleeding with proton pump inhibitor therapy in acute venous thromboembolism: pilot randomized trial (radiant trial)Omeprazole | Ottawa Hospital Research Institute | Ongoing |
| Dec 2, 2022 | A phase 2, multicenter, randomized, open-label, active-control study of REGN9933, a factor xi monoclonal antibody, for prevention of venous thromboembolism…REGN9933 | Regeneron | Ongoing |
| Jan 7, 2022 | A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous pixaban on…Abelacimab | Anthos Therapeutics, Inc. | Ongoing |
| Oct 29, 2021 | Treatment of cvd with lose dose rivaroxaban in advanced CKD (TRACK)Rivaroxaban | The George Institute for Global Health | Closed |
| Oct 21, 2021 | Primary thromboprophylaxis in patients with malignancy and central venous catheters: a randomized controlled trial (trim-line)Rivaroxaban | Ottawa Hospital Research Institute | Ongoing |
| Dec 3, 2020 | Towards improved adherence with extended vte prophylaxis after abdominal or pelvic major cancer surgeryApixaban | Hamilton Health Sciences Corporation | Closed |
| Jul 28, 2020 | The saver trial: statins for venous event reduction in patients with venous thromboembolismRosuvastatin | Ottawa Hospital Research Institute | Ongoing |
| Dec 13, 1989 | ATnativFor the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when… | Pharmacia & Upjohn AB | Approved |
| Apr 8, 2024 | TecarfarinPrevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist… | Cadrenal Therapeutics | Designated |
| Mar 7, 2019 | TecarfarinPrevention of systemic thromboembolism of cardiac origin in patients with End Stage Renal Disease and atrial fibrillation | Cadrenal Therapeutics, Inc. | Designated |
| Nov 21, 2025 | Svariya (previously Rivaroxaban Koanaa)Rivaroxaban · generic | PGF Pharma International d.o.o. | EMA ↗ |
| Feb 19, 2024 | Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)Dabigatran etexilate · generic | Teva GmbH | EMA ↗ |
| May 26, 2023 | Dabigatran Etexilate AccordDabigatran etexilate · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Nov 12, 2021 | Rivaroxaban Viatris (previously Rivaroxaban Mylan)Rivaroxaban · generic | Viatris Limited | EMA ↗ |
| May 19, 2021 | LydisilkaEstetrol; drospirenone | Estetra SPRL | EMA ↗ |
| Nov 16, 2020 | Rivaroxaban AccordRivaroxaban · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jul 23, 2020 | Apixaban AccordApixaban · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Sep 15, 2016 | InhixaEnoxaparin sodium · biosimilar | Techdow Pharma Netherlands B.V. | EMA ↗ |
| May 18, 2011 | EliquisApixaban | Bristol-Myers Squibb / Pfizer EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA